Blue­bird’s reg­u­la­to­ry chief de­parts two days af­ter his­toric gene ther­a­py nod to join Flag­ship’s Tessera

Just two days af­ter se­cur­ing FDA ap­proval for the first gene ther­a­py for a chron­ic con­di­tion, blue­bird bio’s chief reg­u­la­to­ry of­fi­cer was on to her next jour­ney.

Af­ter an 11-year ca­reer at blue­bird, Anne-Vir­ginie Eggi­mann has moved over to Tessera Ther­a­peu­tics, the Flag­ship-in­cu­bat­ed biotech that re­cent­ly at­tract­ed for­mer Ab­b­Vie vice chair Michael Sev­eri­no as CEO. She’ll hold the same post at her new em­ploy­er, which is at­tempt­ing to cre­ate the field of “gene writ­ing.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER